Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals
05 sept. 2023 08h30 HE
|
Travere Therapeutics, Inc.
• Travere received $210 million at closing and is eligible for up to $235 million in potential sales-based milestone payments• Mirum has acquired Travere’s rights and assets related to Cholbam® and...
Travere Therapeutics to Present at the 2023 Wells Fargo Healthcare Conference
31 août 2023 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the 2023 Wells Fargo Healthcare Conference on Thursday,...
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023
24 août 2023 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company will present clinical data from the Phase 1/2 COMPOSE Study of pegtibatinase,...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
14 août 2023 17h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on August 10, 2023, the Compensation Committee of its Board of Directors granted...
Travere Therapeutics Reports Second Quarter 2023 Financial Results
03 août 2023 16h01 HE
|
Travere Therapeutics, Inc.
• Received 417 new patient start forms for FILSPARI™(sparsentan) in the second quarter 2023, reflecting continued strong demand from nephrologists and patients with IgA nephropathy (IgAN) • ...
Travere Therapeutics to Report Second Quarter 2023 Financial Results
20 juil. 2023 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2023 financial results on Thursday, August 3, 2023, after the...
Travere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum Pharmaceuticals
17 juil. 2023 08h00 HE
|
Travere Therapeutics, Inc.
• Mirum to acquire all of Travere’s rights and assets related to Cholbam® and Chenodal® • Travere to receive up to $445 million with $210 million upfront and up to $235 million in potential...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11 juil. 2023 17h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, July 11, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on July 10, 2023, the Compensation Committee of its Board of Directors granted inducement...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
14 juin 2023 17h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on June 10, 2023, the Compensation Committee of its Board of Directors granted...
Travere Therapeutics Announces Presentations of Abstracts at the 60th European Renal Association (ERA) Congress 2023
08 juin 2023 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, June 08, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present nine abstracts, including the interim...